Proactive Investors - Run By Investors For Investors

OptiBiotix Health enters precision nutrition field with Spanish LPLDL licensing deal

IENP has developed a test that analyses gut bacteria, the results from which it uses to place customers on a targeted food supplement regime to help boost their microbiome
The deal gives IENP non-exclusive rights to use LPLDL in its products

A Spanish foods giant has signed a licensing agreement to use OptiBiotix Health PLC’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain in some of its products.

The agreement gives Instituto Español de Nutrición Personalizada (IENP) non-exclusive rights to manufacture and market food supplements containing LPLDL in Spain for the next three years.

IENP is the precision nutrition branch of CAPSA Food, one of Spain’s largest food conglomerates which turns over more than €700mln a year.

READ: Opti sets launch date for weight management product

It has developed a test that analyses gut microbiome – the bacteria living in the intestine – which it then uses to place customers on different, targeted food supplement regimes to help get their microbiome back to healthy.

Under the terms of the deal, IENP will use its network to market the product in supermarkets, department stores, pharmacies, and online across Spain.

“We are delighted to enter the field of personalised and precision nutrition, one of the fastest-growing and highest-value sectors within the food industry,” said OptiBiotix’s business development director, Luis Gosálbez.

“Within two years of launch, we now have products being sold by numerous partners in over 30 countries around the world.

“We see this agreement as another step to growing revenues, market presence, and brand value of LPLDL, the 'Intel' inside a wide range of products in consumer and pharmaceutical markets around the world.”

View full OPTI profile View Profile

OptiBiotix Health PLC Timeline

Related Articles

April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
harley street
May 10 2019
Work at Advanced Onco’s Harley Street facility is due to complete within the next few months, and the first patient treated by LIGHT is slated for the second half of 2020
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use